Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2025-11-11 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
关于首次公开发行前已发行股份解除限售并上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the lifting of restrictions on previously issued shares before the company's initial public offering (IPO) and their subsequent listing and circulation. It includes specifics about the number of shares, shareholders involved, lock-up periods, commitments by controlling shareholders and management, and the schedule for the shares to become freely tradable. The document also contains legal and regulatory compliance statements and the opinion of the sponsoring institution. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a dividend notice, earnings release, or management report. The content focuses on share capital changes related to the lifting of share restrictions and listing of shares for trading. This fits the definition of a Share Issue/Capital Change (SHA) filing, which covers announcements regarding new share issues, stock splits, or other capital changes such as lifting share restrictions and listing previously restricted shares for trading.
2025-11-11 Chinese
关于签署合作开发及许可协议的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about signing a cooperation development and licensing agreement with another company. It details the agreement's background, scope, and potential impact on the company. There is no financial data, no quarterly or annual report content, no audit information, no voting results, no management changes, no earnings release, and no regulatory certification. The document is relatively short (2319 characters) and serves as a disclosure of a corporate agreement rather than a financial or regulatory report. Therefore, it fits best into the category of a Regulatory Filing (RNS), which is a fallback for miscellaneous announcements that do not fit other specific categories.
2025-10-28 Chinese
关于注销部分募集资金专项账户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation of certain special accounts for raised funds (募集资金专项账户的注销). It details the completion of the account closure procedures, the transfer of funds, and related regulatory approvals. The document does not contain financial statements or detailed financial data but is a formal notification about the status of fundraising accounts and their management. It is not an annual report, interim report, or earnings release. It is also not a regulatory certification or officer attestation. The document fits best as a Capital/Financing Update (CAP) because it relates to the management and status of capital raised through stock issuance and the handling of those funds.
2025-10-23 Chinese
第六届董事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from 新天地药业股份有限公司 regarding the approval of the 2025 third quarter report. It states that the board has reviewed and approved the report, but the actual report content is disclosed separately on a public information website (巨潮资讯网). The document is short (1003 characters) and primarily announces the board's approval and meeting details rather than containing the full quarterly report or substantive financial data. According to the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself. Therefore, the appropriate classification is a Regulatory Filing (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2025-10-21 Chinese
第六届监事会第八次会议决议公告
Report Publication Announcement Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Xintiandi Pharmaceutical Co., Ltd. regarding the approval of the company's 2025 third quarter report. It states that the company has prepared the 2025 third quarter report in accordance with relevant laws and regulations, and that the detailed report is disclosed on the CNINFO website. The document itself does not contain the actual financial statements or substantive financial data of the quarterly report but rather announces the approval and points to the full report elsewhere. The document length is short (1032 characters), and it serves as an announcement of the report rather than the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR).
2025-10-21 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025 年第三季度报告" which translates to "2025 Third Quarter Report." It contains detailed financial data including income, profit, cash flow, assets, liabilities, equity, and shareholder information for the third quarter period ending September 30, 2025. The presence of comprehensive financial statements such as consolidated balance sheet and profit and loss statement, along with management assurances about the accuracy and completeness of the report, clearly indicates this is a quarterly financial report. The document length is substantial (15,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-10-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.